BGI Genomics Co., Ltd. (SHE:300676)
China
· Delayed Price · Currency is CNY 57.96
+0.10 (0.17%)
May 14, 2025, 1:45 PM CST
BGI Genomics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -902.69 | 92.9 | 802.77 | 1,462 | 2,090 | Upgrade
|
| Depreciation & Amortization | 469.23 | 436.84 | 453.07 | 370.6 | 302.33 | Upgrade
|
| Other Amortization | 85.94 | 47.4 | 34.61 | 25.82 | 25.89 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.63 | -2.76 | -0.11 | 3.88 | 4.23 | Upgrade
|
| Asset Writedown & Restructuring Costs | 193.76 | 9.25 | 209.24 | 102.24 | 105.02 | Upgrade
|
| Loss (Gain) From Sale of Investments | 87.41 | 33.07 | -388.21 | -260.29 | -153.32 | Upgrade
|
| Provision & Write-off of Bad Debts | 197.1 | 66.41 | 185.1 | 104.56 | 140.86 | Upgrade
|
| Other Operating Activities | 14.52 | 82.53 | 325.54 | 130.7 | 131.05 | Upgrade
|
| Change in Accounts Receivable | -438.84 | 736.49 | -1,086 | 254.15 | -471.96 | Upgrade
|
| Change in Inventory | -34.2 | 103.78 | 46.25 | 169.94 | -603.7 | Upgrade
|
| Change in Accounts Payable | 284.49 | -1,345 | -484.64 | 147.51 | 2,117 | Upgrade
|
| Change in Other Net Operating Assets | 115.5 | 122.81 | 22.85 | - | - | Upgrade
|
| Operating Cash Flow | 95.72 | 408.77 | 130.88 | 2,476 | 3,603 | Upgrade
|
| Operating Cash Flow Growth | -76.58% | 212.31% | -94.71% | -31.27% | 1506.52% | Upgrade
|
| Capital Expenditures | -529.48 | -1,236 | -1,267 | -383.52 | -301.15 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.56 | 2.72 | 0.33 | 0.71 | 4.04 | Upgrade
|
| Cash Acquisitions | - | - | 5.2 | - | - | Upgrade
|
| Divestitures | - | - | -0.01 | 5.91 | - | Upgrade
|
| Investment in Securities | 116.67 | -763.71 | 569.72 | -2,069 | 431.01 | Upgrade
|
| Other Investing Activities | 97.83 | 246.64 | 111.31 | 153.44 | 60.08 | Upgrade
|
| Investing Cash Flow | -314.42 | -1,751 | -580.07 | -2,292 | 193.98 | Upgrade
|
| Long-Term Debt Issued | 192.8 | 251.68 | 20 | 5 | 1,289 | Upgrade
|
| Total Debt Issued | 192.8 | 251.68 | 20 | 5 | 1,289 | Upgrade
|
| Long-Term Debt Repaid | -94.96 | -78.77 | -780.21 | -690.2 | -60.42 | Upgrade
|
| Total Debt Repaid | -94.96 | -78.77 | -780.21 | -690.2 | -60.42 | Upgrade
|
| Net Debt Issued (Repaid) | 97.84 | 172.91 | -760.21 | -685.2 | 1,228 | Upgrade
|
| Issuance of Common Stock | 53.08 | 82.85 | - | 2,003 | - | Upgrade
|
| Repurchase of Common Stock | -780.52 | - | -336.74 | - | -482.32 | Upgrade
|
| Common Dividends Paid | -50.36 | -416.73 | -167.13 | -177.78 | -62.29 | Upgrade
|
| Other Financing Activities | -3.18 | -105.91 | 69.54 | -102.79 | 466.78 | Upgrade
|
| Financing Cash Flow | -683.15 | -266.88 | -1,195 | 1,037 | 1,150 | Upgrade
|
| Foreign Exchange Rate Adjustments | 45.12 | 32.82 | 279.38 | -139.91 | -262.52 | Upgrade
|
| Net Cash Flow | -856.72 | -1,576 | -1,364 | 1,081 | 4,685 | Upgrade
|
| Free Cash Flow | -433.76 | -827.62 | -1,136 | 2,093 | 3,302 | Upgrade
|
| Free Cash Flow Growth | - | - | - | -36.62% | - | Upgrade
|
| Free Cash Flow Margin | -11.22% | -19.03% | -16.10% | 30.93% | 39.32% | Upgrade
|
| Free Cash Flow Per Share | -1.05 | -2.01 | -2.77 | 5.08 | 8.27 | Upgrade
|
| Cash Income Tax Paid | 204.03 | 144.8 | 336.02 | 419.82 | 490.87 | Upgrade
|
| Levered Free Cash Flow | -932.68 | -467.62 | -619.14 | 1,633 | 2,799 | Upgrade
|
| Unlevered Free Cash Flow | -900.17 | -410.4 | -556.16 | 1,698 | 2,855 | Upgrade
|
| Change in Net Working Capital | 581.03 | -271.16 | 343 | -635.08 | -1,080 | Upgrade
|
Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.